Zila's Inter-Cal Nutraceuticals Unit Files for International Patent On Ester-C(R) Cancer Treatment

Apr 26, 2001, 01:00 ET from Zila, Inc.

    PHOENIX, April 26 /PRNewswire/ -- Inter-Cal Nutraceuticals, a division of
 Zila, Inc. (Nasdaq:   ZILA) and developer of branded, value-added ingredients
 and technologies for the global nutritional and cosmeceutical industries,
 announced that based on preliminary independent research, the Company has
 applied for an international patent covering the use of Ester-C(R) mineral
 ascorbate to treat cancer in humans.
     Michelle Michels, Vice President and General Manager of Inter-Cal,
 cautioned, "While we are excited about the potential cancer treatment value of
 our product, significantly more research is required before any health claims
 can be made.  More laboratory work, plus in vivo testing has to be performed.
 The Company is exploring potential partnerships with other, more
 cancer-directed companies to finance further drug development efforts based
 upon Zila's cancer management technologies."
     Michels continued, "As Inter-Cal explores a wide variety of potential
 human and animal applications for our patented technology, we will continue to
 market our growing Ester-C line of innovative ingredients for nutraceuticals,
 cosmeceuticals, personal care products, foods, beverages, pet foods and animal
 supplements."
     The international patent application followed completion of pre-clinical
 research indicating that Ester-C mineral ascorbate, which is enriched with
 vitamin C metabolites, selectively kills a variety of cancer cell types.
 Ester-C mineral ascorbate produced a minimum two-fold increase in cancer cell
 death rate, at lower concentration, compared to the performance of mineral
 ascorbate alone or ascorbic acid (plain vitamin C).
     The research was performed by Raxit J. Jariwalla, PhD, principal
 investigator at the California Institute for Medical Research, an independent,
 non-profit research institution affiliated with and located on the campus of
 Santa Clara Valley Medical Center in San Jose, California.  Dr. Jariwalla is
 the former Director of the Viral Carcinogenesis and Immune Deficiency Program
 of the Linus Pauling Institute of Science and Medicine.
     "Prior research has shown that plain ascorbic acid can reduce cancer cell
 growth and viability, but there is a paucity of research on the ability of
 ascorbic acid or its metabolites to actually kill cancer cells," Michels said.
 "Dr. Jariwalla observed a selective cell-killing effect with plain vitamin C
 or mineral ascorbate, and a higher level of tumor-specific cell death with
 Ester-C mineral ascorbate.  This enhancement of effectiveness was noted in
 tests on a variety of human cancer cell types, including skin, liver, nerve
 and colon."
     Michels said that based on this research, the Company filed an
 international patent application for "tumor-cytotoxic chemotherapeutic methods
 and compositions for treating cancers in a human host."  The patent
 application describes administering the Ester-C material intravenously to
 bring it in contact with tumor cells, with subsequent oral administration in
 some cases.
 
     Headquartered in Phoenix, Arizona, USA, Zila produced $77 million revenue
 in fiscal 2000.  The Company has six divisions:  Zila Consumer
 Pharmaceuticals, marketer of Zilactin(R) oral healthcare products; Zila
 Professional Pharmaceuticals, marketer of Peridex(R) prescription mouthrinse,
 OraTest(R) oral cancer detection products, and the Pro-Ties(TM) bundling
 system for instrument sterilization; Zila Dental Supply(TM), a national dental
 supplies distributor; Inter-Cal Nutraceuticals, manufacturer and supplier of
 patented Ester-C(R) branded products and botanicals such as Palmettx(TM) saw
 palmetto extract -- value-added ingredients for the global nutrition industry;
 Zila Europe, marketer of OraTest(R) products in the EU; and Zila Technical
 Operations, manufacturer of pharmaceutical-grade Zila(R) Tolonium Chloride, as
 well as dry-handled pre-moistened swab products at its Innovate Swab
 Technologies unit, and internal source of product development, technical and
 compliance expertise.  For Company or product information, visit www.zila.com;
 register at "Investor Relations/Email Alert" for e-mail notification of
 Company news.
 
     This document contains forward-looking statements within the meaning of
 Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934.  These forward-looking statements are based largely on
 Zila's expectations or forecasts of future events, can be affected by
 inaccurate assumptions and are subject to various business risks and known and
 unknown uncertainties, a number of which are beyond the Company's control.
 Therefore, actual results could differ materially from the forward-looking
 statements contained herein.  A wide variety of factors could cause or
 contribute to such differences and could adversely impact revenues,
 profitability, cash flows and capital needs.  There can be no assurance that
 the forward-looking statements contained in this document will, in fact,
 transpire or prove to be accurate.  For a more detailed description of these
 and other cautionary factors that may affect Zila's future results, please
 refer to Zila's annual report on Form 10-K for its fiscal year ended July 31,
 2000, filed with the US Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X86807887
 
 

SOURCE Zila, Inc.
    PHOENIX, April 26 /PRNewswire/ -- Inter-Cal Nutraceuticals, a division of
 Zila, Inc. (Nasdaq:   ZILA) and developer of branded, value-added ingredients
 and technologies for the global nutritional and cosmeceutical industries,
 announced that based on preliminary independent research, the Company has
 applied for an international patent covering the use of Ester-C(R) mineral
 ascorbate to treat cancer in humans.
     Michelle Michels, Vice President and General Manager of Inter-Cal,
 cautioned, "While we are excited about the potential cancer treatment value of
 our product, significantly more research is required before any health claims
 can be made.  More laboratory work, plus in vivo testing has to be performed.
 The Company is exploring potential partnerships with other, more
 cancer-directed companies to finance further drug development efforts based
 upon Zila's cancer management technologies."
     Michels continued, "As Inter-Cal explores a wide variety of potential
 human and animal applications for our patented technology, we will continue to
 market our growing Ester-C line of innovative ingredients for nutraceuticals,
 cosmeceuticals, personal care products, foods, beverages, pet foods and animal
 supplements."
     The international patent application followed completion of pre-clinical
 research indicating that Ester-C mineral ascorbate, which is enriched with
 vitamin C metabolites, selectively kills a variety of cancer cell types.
 Ester-C mineral ascorbate produced a minimum two-fold increase in cancer cell
 death rate, at lower concentration, compared to the performance of mineral
 ascorbate alone or ascorbic acid (plain vitamin C).
     The research was performed by Raxit J. Jariwalla, PhD, principal
 investigator at the California Institute for Medical Research, an independent,
 non-profit research institution affiliated with and located on the campus of
 Santa Clara Valley Medical Center in San Jose, California.  Dr. Jariwalla is
 the former Director of the Viral Carcinogenesis and Immune Deficiency Program
 of the Linus Pauling Institute of Science and Medicine.
     "Prior research has shown that plain ascorbic acid can reduce cancer cell
 growth and viability, but there is a paucity of research on the ability of
 ascorbic acid or its metabolites to actually kill cancer cells," Michels said.
 "Dr. Jariwalla observed a selective cell-killing effect with plain vitamin C
 or mineral ascorbate, and a higher level of tumor-specific cell death with
 Ester-C mineral ascorbate.  This enhancement of effectiveness was noted in
 tests on a variety of human cancer cell types, including skin, liver, nerve
 and colon."
     Michels said that based on this research, the Company filed an
 international patent application for "tumor-cytotoxic chemotherapeutic methods
 and compositions for treating cancers in a human host."  The patent
 application describes administering the Ester-C material intravenously to
 bring it in contact with tumor cells, with subsequent oral administration in
 some cases.
 
     Headquartered in Phoenix, Arizona, USA, Zila produced $77 million revenue
 in fiscal 2000.  The Company has six divisions:  Zila Consumer
 Pharmaceuticals, marketer of Zilactin(R) oral healthcare products; Zila
 Professional Pharmaceuticals, marketer of Peridex(R) prescription mouthrinse,
 OraTest(R) oral cancer detection products, and the Pro-Ties(TM) bundling
 system for instrument sterilization; Zila Dental Supply(TM), a national dental
 supplies distributor; Inter-Cal Nutraceuticals, manufacturer and supplier of
 patented Ester-C(R) branded products and botanicals such as Palmettx(TM) saw
 palmetto extract -- value-added ingredients for the global nutrition industry;
 Zila Europe, marketer of OraTest(R) products in the EU; and Zila Technical
 Operations, manufacturer of pharmaceutical-grade Zila(R) Tolonium Chloride, as
 well as dry-handled pre-moistened swab products at its Innovate Swab
 Technologies unit, and internal source of product development, technical and
 compliance expertise.  For Company or product information, visit www.zila.com;
 register at "Investor Relations/Email Alert" for e-mail notification of
 Company news.
 
     This document contains forward-looking statements within the meaning of
 Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934.  These forward-looking statements are based largely on
 Zila's expectations or forecasts of future events, can be affected by
 inaccurate assumptions and are subject to various business risks and known and
 unknown uncertainties, a number of which are beyond the Company's control.
 Therefore, actual results could differ materially from the forward-looking
 statements contained herein.  A wide variety of factors could cause or
 contribute to such differences and could adversely impact revenues,
 profitability, cash flows and capital needs.  There can be no assurance that
 the forward-looking statements contained in this document will, in fact,
 transpire or prove to be accurate.  For a more detailed description of these
 and other cautionary factors that may affect Zila's future results, please
 refer to Zila's annual report on Form 10-K for its fiscal year ended July 31,
 2000, filed with the US Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X86807887
 
 SOURCE  Zila, Inc.